sabirnetug (ACU193)
ACU193-102
Phase 1 small_molecule completed
Quick answer
sabirnetug (ACU193) for Alzheimer Disease is a Phase 1 program (small_molecule) at Acumen Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Acumen Pharmaceuticals
- Indication
- Alzheimer Disease
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed